|
26/04/2024
|
07:00
|
Cancellation - C4X Discovery Holdings plc
|
RNS
|
|
25/04/2024
|
07:00
|
Last day of dealings and update on cancellation
|
RNS
|
|
23/04/2024
|
15:35
|
Holding(s) in Company
|
RNS
|
|
19/04/2024
|
18:00
|
C4X Discovery Holdings
|
RNS
|
|
15/04/2024
|
12:37
|
Result of General Meeting
|
RNS
|
|
09/04/2024
|
10:58
|
Director/PDMR Share Purchases
|
RNS
|
|
27/03/2024
|
07:00
|
Proposed Voluntary Delisting
|
RNS
|
|
27/03/2024
|
07:00
|
Interim results
|
RNS
|
|
23/01/2024
|
13:57
|
Result of AGM
|
RNS
|
|
18/01/2024
|
07:00
|
Board Update
|
RNS
|
|
04/01/2024
|
14:45
|
Holding(s) in Company
|
RNS
|
|
03/01/2024
|
07:00
|
AstraZeneca $11m milestone payment to C4XD
|
RNS
|
|
18/12/2023
|
15:31
|
Posting of 2023 Annual Report and Notice of AGM
|
RNS
|
|
14/12/2023
|
07:00
|
Full Year Results
|
RNS
|
|
07/12/2023
|
07:00
|
Notice of Results
|
RNS
|
|
05/10/2023
|
14:35
|
Holding(s) in Company
|
RNS
|
|
02/10/2023
|
12:36
|
Block listing Interim Review
|
RNS
|
|
29/09/2023
|
11:14
|
Grant of Options and Directors Dealing
|
RNS
|
|
28/09/2023
|
15:52
|
Holding(s) in Company
|
RNS
|
|
01/09/2023
|
07:00
|
Total Voting Rights
|
RNS
|
|
18/08/2023
|
12:45
|
Exercise of Options, Issue of Equity and TVR
|
RNS
|
|
01/08/2023
|
07:00
|
Divestment of Orexin-1 to Indivior for £15.95m
|
RNS
|
|
20/06/2023
|
07:00
|
C4X Discovery Holdings plc: Board Change
|
RNS
|
|
01/06/2023
|
07:00
|
MALT-1 Inhibitor Programme Update
|
RNS
|
|
26/04/2023
|
07:00
|
Half Year Results
|
RNS
|
|
19/04/2023
|
07:00
|
Notice of Results
|
RNS
|
|
08/03/2023
|
14:49
|
Block Listing Interim Review
|
RNS
|
|
22/02/2023
|
07:00
|
C4XD and Garvan Institute collaboration
|
RNS
|
|
24/01/2023
|
11:47
|
Result of AGM
|
RNS
|
|
19/01/2023
|
07:00
|
MALT-1 Inhibitor Programme Update
|
RNS
|
|
10/01/2023
|
07:00
|
Nick Ray Appointed as Chief Scientific Officer
|
RNS
|
|
19/12/2022
|
16:52
|
Posting of 2022 Annual Report and Notice of AGM
|
RNS
|
|
15/12/2022
|
07:00
|
Full Year Results
|
RNS
|
|
28/11/2022
|
14:31
|
C4X Discovery signs potential $402mln deal
|
EQS Group
|
|
28/11/2022
|
09:00
|
Notice of Final Results
|
RNS
|
|
28/11/2022
|
07:00
|
C4XD Agreement with AstraZeneca
|
RNS
|
|
01/11/2022
|
14:03
|
Exercise of Options, Issue of Equity and TVR
|
RNS
|
|
20/10/2022
|
07:00
|
C4XD and HitGen to collaborate in inflammation
|
RNS
|
|
04/10/2022
|
14:56
|
Holding(s) in Company
|
RNS
|
|
22/09/2022
|
16:40
|
Second Price Monitoring Extn
|
RNS
|
|
22/09/2022
|
16:35
|
Price Monitoring Extension
|
RNS
|
|
31/08/2022
|
11:10
|
Holding(s) in Company
|
RNS
|
|
17/08/2022
|
16:06
|
Holding(s) in Company
|
RNS
|
|
17/08/2022
|
15:43
|
Holding(s) in Company
|
RNS
|
|
16/08/2022
|
14:17
|
Holding(s) in Company
|
RNS
|
|
11/08/2022
|
12:43
|
Result of Placing to Raise £5.7 million
|
RNS
|
|
11/08/2022
|
07:00
|
Proposed Placing to Raise Up To £5.7 million
|
RNS
|
|
02/08/2022
|
07:00
|
Business Update
|
RNS
|
|
01/08/2022
|
15:09
|
Block Listing Interim Review
|
RNS
|
|
06/07/2022
|
07:00
|
C4X Discovery receives Sanofi milestone payment
|
RNS
|